Showing 451-460 of 5061 results for "".
- Soliton Appoints Sean J. Shapiro as Vice President of Saleshttps://practicaldermatology.com/news/soliton-appoints-sean-j-shapiro-as-vice-president-of-sales/2460643/Sean J. Shapiro is Soliton, Inc’s New Vice President of Sales, effective January 1, 2021. "We are very excited to have Sean join our team during this pivotal time for the company as we anticipate clearance of our 510(k) application for cellulite reduction duri
- LEO Pharma Taps Jörg Möller as EVP, Global Research and Developmenthttps://practicaldermatology.com/news/leo-pharma-taps-jorg-moller-as-evp-global-research-and-development/2460636/Jörg Möller is joining LEO Pharma A/S’s Global Leadership Team as Executive Vice President (EVP), Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pha
- Three-Part Acne Scar Protocol Shows Progressive Changes Through 139 Dayshttps://practicaldermatology.com/news/three-part-acne-scar-protocol-shows-progressive-changes-through-139-days/2488104/A multimodal protocol combining subcision, injectable treatment, and fractional laser therapy was associated with reductions in facial atrophic acne scar dimensions in a prospective case series published in Biomedicines. Ultrasound Tracks Changes Through 139 Days The stud
- Fish Oil With Low-Dose Isotretinoin Shows Noninferior Acne Controlhttps://practicaldermatology.com/news/fish-oil-with-low-dose-isotretinoin-shows-noninferior-acne-control/2488054/Fish oil supplementation added to low-dose isotretinoin was noninferior to isotretinoin alone for reducing acne lesions and may help preserve skin hydration and limit increases in triglyceride levels, according to findings published in the
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://practicaldermatology.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi
- Dr. Kevin Pinski Presents Injectable Pearls at Noahhttps://practicaldermatology.com/news/dr-kevin-pinski-presents-injectable-pearls-at-noah/2486902/At the 67th Noah Worcester Dermatological Society Annual Meeting, Kevin Pinski, MD, presented “Injectable Pearls,” drawing on nearly 4 decades of experience with neuromodulators, fillers, and cosmetic injectables. The presentation covered practical techniques, pati
- Dr. Lisa Swanson Presents on Communication, Therapeutics, and Confidence in Treating Children at Noahhttps://practicaldermatology.com/news/dr-lisa-swanson-presents-on-communication-therapeutics-and-confidence-in-treating-children-at-noah/2486876/At the 67th Noah Worcester Dermatological Society Annual Meeting, Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, delivered the Alfred L. Weiner Lecture titled “Afraid to Treat Kids? Here are some Pearls to Help!” The session focused on practical, clinic-ready stra
- Imaging Bests Exam in Detecting Nodal Metastases in High-Risk cSCChttps://practicaldermatology.com/news/imaging-bests-exam-in-detecting-nodal-metastases-in-high-risk-cscc/2486802/Ultrasonography and computed tomography (CT) outperformed physical examination for detecting baseline nodal metastases in high-risk cutaneous squamous cell carcinoma (cSCC). Investigators for the prospective, multicenter diagnostic study evaluated baseline staging modalities for detecting
- Transcriptomic Study Identifies IL-1β Axis in Hidradenitis Suppurativahttps://practicaldermatology.com/news/transcriptomic-study-identifies-il-1b-axis-in-hidradenitis-suppurativa/2486448/Comprehensive transcriptomic profiling of hidradenitis suppurativa (HS) highlights a dominant macrophage-derived IL-1β/NLRP3 inflammasome axis, p
- IMMpactful: Risankizumab Outperforms Deucravacitinib in Moderate Psoriasis at 16 Weekshttps://practicaldermatology.com/news/immpactful-risankizumab-outperforms-deucravacitinib-in-moderate-psoriasis-at-16-weeks/2486443/Risankizumab achieved higher rates of PASI 90 and PASI 100 compared with deucravacitinib at 16 weeks, alongside greater improvements in patient-reported symptoms and quality of life, new results from the IMMpactful trial suggested.